[Skip to Content]
[Skip to Content Landing]
Views 234
Citations 0
Comment & Response
March 2016

Treatment Recommendations for Patients With a Diagnosis of Ductal Carcinoma In Situ

Author Affiliations
  • 1Section of Biostatistics, University of Copenhagen, Denmark
  • 2Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway
  • 3School of Life Sciences and Medicine, King’s College, London, England

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Oncol. 2016;2(3):398. doi:10.1001/jamaoncol.2015.4863

To the Editor The large register study by Narod et al1 reported breast cancer–specific mortality after a ductal carcinoma in situ (DCIS) diagnosis with special focus on the influence of initial treatment received. There are 2 methodological problems with this article.

First, by using the Kaplan-Meier approach to mortality curves (Figures 1 and 2, eFigures 1-8 in the Supplement) the authors essentially predicted the uninterpretable mortality in a world where all causes of death other than breast cancer were eliminated.2 The relevant target is the probability of dying of breast cancer before dying of other causes, estimable as the so-called cumulative incidence (see Falk et al3 for a correct analysis in a similar national study of DCIS from Norway, notably not cited by Narod et al1).

First Page Preview View Large
First page PDF preview
First page PDF preview